Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen Utikal
Selma Ugurel

Showing results (331-340 of 490) with videos related to

Pageof 49
Sort By:
European Journal of Cancer (Oxford, England : 1990)|August 30, 2024
Early versus late response to PD-1-based immunotherapy in metastatic melanomaGeorg C Lodde, Fang Zhao, Rudolf Herbst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100BAnnette Paschen, Antje Sucker, Bettina Hill, et al.
Pigment Cell Research|July 11, 2006
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signatureKeith S Hoek, Natalie C Schlegel, Patricia Brafford, et al.
British Journal of Cancer|February 18, 2020
T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cellsKarol Granados, Laura Hüser, Aniello Federico, et al.
Cancers|November 26, 2022
Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in MelanomaNadine L Ammann, Yasmin F Schwietzer, Christian Mess, et al.
International Journal of Cancer|May 28, 2019
Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic targetElias Orouji, Aniello Federico, Lionel Larribère, et al.
Cancer Research|November 2, 2017
CCR5<sup>+</sup> Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma LesionsCarolin Blattner, Viktor Fleming, Rebekka Weber, et al.
Plos One|May 26, 2018
Willingness to pay for a cure of low-risk melanoma patients in GermanyMatthias Augustin, Christine Blome, Andrea Forschner, et al.
International Journal of Molecular Sciences|September 28, 2023
Flagellin-Induced Immune Response in Human-Induced Pluripotent Stem Cell-Derived CardiomyocytesGoekhan Yuecel, Xiaobo Zhou, Linda Terkatz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2015
Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with IpilimumabChristoffer Gebhardt, Alexandra Sevko, Huanhuan Jiang, et al.
Pageof 49

Showing results (331-340 of 490) with videos related to

Sort By:
Pageof 49
European Journal of Cancer (Oxford, England : 1990)|August 30, 2024
Early versus late response to PD-1-based immunotherapy in metastatic melanomaGeorg C Lodde, Fang Zhao, Rudolf Herbst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100BAnnette Paschen, Antje Sucker, Bettina Hill, et al.
Pigment Cell Research|July 11, 2006
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signatureKeith S Hoek, Natalie C Schlegel, Patricia Brafford, et al.
British Journal of Cancer|February 18, 2020
T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cellsKarol Granados, Laura Hüser, Aniello Federico, et al.
Cancers|November 26, 2022
Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in MelanomaNadine L Ammann, Yasmin F Schwietzer, Christian Mess, et al.
International Journal of Cancer|May 28, 2019
Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic targetElias Orouji, Aniello Federico, Lionel Larribère, et al.
Cancer Research|November 2, 2017
CCR5<sup>+</sup> Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma LesionsCarolin Blattner, Viktor Fleming, Rebekka Weber, et al.
Plos One|May 26, 2018
Willingness to pay for a cure of low-risk melanoma patients in GermanyMatthias Augustin, Christine Blome, Andrea Forschner, et al.
International Journal of Molecular Sciences|September 28, 2023
Flagellin-Induced Immune Response in Human-Induced Pluripotent Stem Cell-Derived CardiomyocytesGoekhan Yuecel, Xiaobo Zhou, Linda Terkatz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2015
Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with IpilimumabChristoffer Gebhardt, Alexandra Sevko, Huanhuan Jiang, et al.
Pageof 49